Who Owns Genmab A/S Stock?
NASDAQ: GMABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 22.06%
- Held by insiders
- 0.00%
- Institutional holders
- 428
- Institutions 22.1%
- Insiders 0.0%
- Public and other 77.9%
Who owns Genmab A/S stock?
Institutional investors own about 22.1% of Genmab A/S's shares, spread across 428 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 0.00% of GMAB.
The largest institutional holders are Darwin Global Management, Ltd. (2.87%), Paradigm Biocapital Advisors LP (2.27%) and Orbis Allan Gray Ltd (1.69%). Together, the top 10 institutions control 13.1% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their GMAB positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of GMAB
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Darwin Global Management, Ltd. | 17.90M | 2.87% | +100.0% |
| Paradigm Biocapital Advisors LP | 14.14M | 2.27% | +7.6% |
| Orbis Allan Gray Ltd | 10.57M | 1.69% | -7.0% |
| Deerfield Management Company, L.P | 6.87M | 1.10% | 0.0% |
| Alliancebernstein L.P. | 6.40M | 1.03% | -25.9% |
| Arrowstreet Capital, Limited Partnership | 6.07M | 0.97% | +22.0% |
| Blackrock Inc. | 6.06M | 0.97% | +29.7% |
| Two Sigma Investments, LP | 5.25M | 0.84% | +49.8% |
| Sofinnova Investments, Inc. | 4.35M | 0.70% | +7.5% |
| Deep Track Capital, Lp | 4.18M | 0.67% | -26.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of GMAB
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Biotechnology ETF | 4.32M | 0.69% |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 3.12M | 0.50% |
| NEW PERSPECTIVE FUND | 3.08M | 0.49% |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 520.70K | 0.08% |
| American Century ETF Trust-Avantis International Equity ETF | 500.72K | 0.08% |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 350.00K | 0.06% |
| RUSSELL INVESTMENT CO-Tax-Managed U.S. Large Cap Fund | 342.34K | 0.05% |
| Tema ETF Trust-Tema Oncology ETF | 183.36K | 0.03% |
| Mercer Funds-Mercer Non-US Core Equity Fund | 179.68K | 0.03% |
| Federated Hermes World Investment Series, Inc.-Federated Hermes Intl L | 172.63K | 0.03% |
Frequently asked questions
Who is the largest shareholder of Genmab A/S?
Darwin Global Management, Ltd. is the largest institutional shareholder of GMAB, owning 2.87% of shares outstanding (17.90M shares) as of its latest 13F filing.
What percentage of Genmab A/S is owned by institutions?
Institutions own about 22.1% of GMAB shares and 22.1% of the public float.
How much of Genmab A/S do insiders own?
Insiders, such as officers and directors, own about 0.00% of GMAB shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.